The immune checkpoint inhibitor durvalumab may have a role in the treatment of EGFR+ tumours with high PD-L1 expression, results from the phase 2 ATLANTIC study show. Published this week in Lancet Oncology the open-label, single-arm trial involved 444 patients with heavily pre-treated advanced non-small cell lung cancer (NSCLC) from 139 study centres in Asia, Europe, ...
ATLANTIC trial shows immune checkpoint inhibitors may have role in advanced NSCLC
By Nicola Garrett
15 Mar 2018